Drug Trial Radar · NCT03959488
A Study to Evaluate the Safety of MEDI8897 for the Prevention of Medically Attended Respiratory Syncytial Virus(RSV) Lower Respiratory Track Infection (LRTI) in High-risk Children
Last checked: Nov 20, 2026Latest source record: Sep 21, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
925
Actual
Start
Jul 30, 2019
Primary completion
May 3, 2021
Study completion Jan 20, 2023
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- First posted
- May 22, 2019
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 0 years, up to 1 year
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the safety and tolerability of MEDI8897 compared to palivizumab when administered to preterm infants entering their first RSV season and children with chronic lung disease (CLD) and congenital heart disease (CHD) entering their first and second RSV season.
Conditions
- Respiratory Syncytial Virus Infections
Interventions
MEDI8897Drug
Anti-RSV monoclonal antibody with an extended half-life
PalivizumabDrug
Approved anti-RSV monoclonal antibody
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety and Tolerability of MEDI8897 as Assessed by the Occurrence of All Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs) and Adverse Events of Special Interest (AESIs) and New Onset Chronic Disease (NOCD)Time frame: 360 days post first dose
Locations
128 sites in 26 countries. Site status is shown where the registry gives one.
Research Site
Anaheim, California
Research Site
Long Beach, California
Research Site
Los Angeles, California
Research Site
National City, California
Research Site
Paramount, California
Research Site
West Covina, California
Research Site
Aurora, Colorado
Research Site
Colorado Springs, Colorado
Research Site
Washington D.C., District of Columbia
Research Site
Atlanta, Georgia
Research Site
Chicago, Illinois
Research Site
Indianapolis, Indiana
Research Site
South Bend, Indiana
Research Site
West Des Moines, Iowa
Research Site
Louisville, Kentucky
Research Site
Jackson, Mississippi
Research Site
Columbia, Missouri
Research Site
Mineola, New York
Research Site
Syracuse, New York
Research Site
Durham, North Carolina
Research Site
Greenville, North Carolina
Research Site
Cincinnati, Ohio
Research Site
Columbus, Ohio
Research Site
Greenville, South Carolina
Research Site
Corpus Christi, Texas
Research Site
Layton, Utah
Research Site
St. George, Utah
Research Site
Charlottesville, Virginia
Research Site
Seattle, Washington
Research Site
Morgantown, West Virginia
Research Site
Graz, Austria
Research Site
Brussels, Belgium
Research Site
Ghent, Belgium
Research Site
Montana, Bulgaria
Research Site
Pazardzhik, Bulgaria
Research Site
Pleven, Bulgaria
Research Site
Plovdiv, Bulgaria
Research Site
Plovdiv, Bulgaria
Research Site
Rousse, Bulgaria
Research Site
Sliven, Bulgaria
Showing 40 of 128 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.